Evidence map›Paper›PMID 37619833›Full record

ArticleThe Journal of investigative dermatology2024

Reduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mice with Diabetes.

Ruchi Roy, Foyez Mahmud, Janet Zayas, Timothy M Kuzel, Jochen Reiser, Sasha H Shafikhani

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ruchi RoyDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Foyez MahmudDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Janet ZayasDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA; Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, Illinois, USA.
Timothy M KuzelDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA; Cancer Center, Rush University Medical Center, Chicago, Illinois, USA.
Jochen ReiserDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Sasha H ShafikhaniDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA; Department of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, Illinois, USA; Cancer Center, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Sasha_Shafikhani@rush.edu.
Rush University Medical Center · US

Funding

Role of immune system in prophylaxis antibiotic's surgical site infection controlR01AI150668 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHAFIKHANI, SASHA H · 2020 to 2024
$2.0M
Factors Leading to Enhanced Pseudomonas Aeruginosa Infection in Diabetic WoundsR01DK107713 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI SHAFIKHANI, SASHA H · 2016 to 2020
$1.7M
Integrated scientific and professional PhD training program in biomedical scienceR25GM109421 · NIGMS · RUSH UNIVERSITY MEDICAL CENTER · PI AL-HARTHI, LENA · 2015 to 2019
$1.4M
Factors Leading to Enhanced Bacterial Infection in Diabetic WoundsF31DK118797 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI ZAYAS, JANET PATRICIA · 2018 to 2019
$90k
NIAID NIH HHS R01 AI150668NIDDK NIH HHS F31 DK118797NIDDK NIH HHS R01 DK107713NIGMS NIH HHS R25 GM109421
6 · The paper itself

Abstract

Diabetic chronic ulcers are plagued with persistent nonresolving inflammation. However, diabetic wound environment early after injury suffers from inadequate inflammatory responses due to reductions in proinflammatory cytokines levels. Diabetic neutrophils have known impairments in bactericidal functions. We hypothesized that reduced bacterial killing by diabetic neutrophils, due to their bactericidal functional impairments, results in reduced bioactive bacterial products, known as pathogen-associated molecular patterns, which in turn contribute to reduced signaling through toll-like receptors, leading to inadequate production of proinflammatory cytokines in infected diabetic wound early after injury. We tested our hypothesis in db/db type 2 obese diabetic mouse wound infection model with Pseudomonas aeruginosa. Our data indicate that despite substantially higher levels of infection, toll-like receptor 4-mediated signaling is reduced in diabetic wounds early after injury owing to reduced bioactive levels of lipopolysaccharide. We further demonstrate that topical treatment with lipopolysaccharide enhances toll-like receptor 4 signaling, increases proinflammatory cytokine production, restores leukocyte trafficking, reduces infection burden, and stimulates healing in diabetic wounds. We posit that lipopolysaccharide may be a viable therapeutic option for the treatment of diabetic foot ulcers if it is applied topically after the surgical debridement process, which is intended to reset chronic ulcers into acute fresh wounds.

Indexed as

Diabetes Mellitus, Type 2Diabetic FootWound InfectionAnimalsAnti-Bacterial AgentsCytokinesImmunityLipopolysaccharidesMicePathogen-Associated Molecular Pattern MoleculesToll-Like Receptor 4Anti-Bacterial AgentsCytokinesLipopolysaccharidesPathogen-Associated Molecular Pattern MoleculesToll-Like Receptor 4

Identifiers

PMID37619833
PMCPMC10840742
OpenAlexW4386056888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.